- Home
- HRL vs MRNA Comparison
HRL vs MRNA Comparison
Compare HRL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRL
- MRNA
- Stock Information
- Founded
- HRL 1891
- MRNA 2010
- Country
- HRL United States
- MRNA United States
- Employees
- HRL N/A
- MRNA N/A
- Industry
- HRL Meat/Poultry/Fish
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HRL Consumer Staples
- MRNA Health Care
- Exchange
- HRL Nasdaq
- MRNA Nasdaq
- Market Cap
- HRL 17.8B
- MRNA 16.5B
- IPO Year
- HRL N/A
- MRNA 2018
- Fundamental
- Price
- HRL $31.90
- MRNA $38.36
- Analyst Decision
- HRL Hold
- MRNA Hold
- Analyst Count
- HRL 6
- MRNA 19
- Target Price
- HRL $32.33
- MRNA $79.50
- AVG Volume (30 Days)
- HRL 2.6M
- MRNA 7.7M
- Earning Date
- HRL 12-04-2024
- MRNA 11-07-2024
- Dividend Yield
- HRL 3.55%
- MRNA N/A
- EPS Growth
- HRL 1.29
- MRNA N/A
- EPS
- HRL 1.47
- MRNA N/A
- Revenue
- HRL $11,920,797,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- HRL $3.77
- MRNA N/A
- Revenue Next Year
- HRL $2.44
- MRNA N/A
- P/E Ratio
- HRL $21.83
- MRNA N/A
- Revenue Growth
- HRL N/A
- MRNA N/A
- 52 Week Low
- HRL $28.51
- MRNA $35.80
- 52 Week High
- HRL $36.86
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- HRL 49.53
- MRNA 35.63
- Support Level
- HRL $32.38
- MRNA $41.06
- Resistance Level
- HRL $33.12
- MRNA $44.38
- Average True Range (ATR)
- HRL 0.73
- MRNA 2.57
- MACD
- HRL -0.07
- MRNA 0.16
- Stochastic Oscillator
- HRL 35.64
- MRNA 1.74
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and become a branded food company. The firm sells its wares through multiple channels, including US retail (64% of fiscal 2023 sales), US food service (30%), and international (6%). By product, 70% of fiscal 2023 sales were from perishable food and 30% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.